Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516341 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

The Antibacterials Market Outlook to 2016

Business Insights, May 2011, Pages: 96


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

This report provides comprehensive coverage of the global antibacterials market, incorporating disease overview, epidemiological analyses of the major indications, market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading antibacterial brands are assessed and five of the market's leading players are profiled.

Features and benefits

- Assess the forecast epidemiology and development of the antibacterials market across the 7MM.

- Analyze the dynamics of the global antibacterials market and understand the impact of key R&D events, market trends, and issues.

- Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.

- Predict revenues for major currently marketed and pipeline antibacterial products over 2010–16

- Develop strategies for success in the future antibacterial market.

Highlights

Of the competing drug classes in global antibacterials market, cephalosporins occupied the leading position with over 25% share followed by penicillins and fluoroquinolones. However, all these drug classes declined in sales in 2010.

Despite high patient numbers, the cost and complexities coupled with regulatory uncertainties and challenges have shifted the investment focus of pharmaceutical manufacturers from antibacterials to treatments for chronic conditions.

Community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) infections are attracting research interest. Additionally, the majority of companies developing new antibiotics are targeting cell wall synthesis inhibitors, DNA topoisomerase II inhibitors, ribosomal inhibitors and methionine tRNA ligase inhibitors.

Your key questions answered

- What are the drivers and resistors of the antibacterials market worldwide?

- What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the antibacterials market?

- What is the forecast commercial potential of the most promising compounds in clinical development?

- Who were the leading players in the global antibacterials market in 2010?

- How have recent launches from companies such as GSK, Pfizer, J&J, Novartis and Merck & Co. performed?



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds